Korro Bio Abandons Lead RNA Editing Drug After Clinical Disappointment, Cuts 34% of Staff
Key Insights
Korro Bio's lead RNA editing therapy KRRO-110 for alpha-1 antitrypsin deficiency (search) failed to produce functional protein at expected levels in early clinical testing.
The company is abandoning its lead program and laying off 34% of staff while shifting to a new delivery approach using sugar molecules.
The setback leaves Korro behind competitors Wave Life Sciences and Airna (search) in the RNA editing space for AATD (search) treatment.
Korro Bio suffered a major setback in the RNA editing field as its lead therapy KRRO-110 failed to meet expectations in early clinical testing for alpha-1 antitrypsin deficiency (search) (AATD (search)), prompting the company to abandon the program and implement significant cost-cutting measures. The company's shares plummeted 80% following the announcement.
Clinical Trial Results Fall Short
KRRO-110 was designed to treat AATD (search), a genetic disorder that occurs when gene variants prevent the body from producing sufficient functioning AAT protein (search), which is critical for protecting the lungs, liver, skin and blood vessels. While the RNA editing therapy did help patients produce functional protein, the levels achieved were significantly below those observed in preclinical testing, according to Korro's late Wednesday announcement.
The company identified the delivery system as a potential issue for the drug's underperformance. This delivery challenge has led Korro to completely pivot its approach, with plans to select a new lead candidate in the first half of next year using a different method for delivering RNA editing treatments into the body.
Major Restructuring and Leadership Changes
The disappointing results triggered immediate organizational changes at Korro Bio. The company announced it would lay off approximately 34% of its staff to extend its cash runway into the second half of 2027. Chief Medical Officer Kemi Olugemo resigned effective immediately following the clinical failure.
Korro ended the third quarter with $102.5 million in cash. The company had raised about $170 million when it went public in 2023 through a reverse merger with Frequency Therapeutics (search), positioning it as one of the leaders in the RNA editing field.
Competitive Landscape Impact
The setback significantly impacts Korro's competitive position in RNA editing for AATD (search). The company now trails rivals including Wave Life Sciences and privately held Airna (search), both of which are advancing their own RNA editing treatments for the same condition.
Additionally, Korro announced that its research collaboration with Novo Nordisk focused on cardiometabolic diseases will be paused for 12 months "to reassess the rationale for the current target under the first research program."
Strategic Pivot Raises Questions
In response to the delivery challenges, Korro is adopting an approach that involves using a type of sugar molecule for drug delivery - a method already employed by some of its competitors. William Blair analyst Myles Minter noted that this choice "goes against the company's own thesis" and raises "concerns about differentiation" in the competitive landscape.
Broader Implications for RNA Editing
Korro's study failure represents another challenge for the RNA editing field, which many researchers consider promising due to its potential for making temporary rather than permanent changes to genetic code. This approach could offer safer and more flexible treatments compared to DNA editing technologies.
The AATD (search) indication remains an area of significant unmet medical need, with major pharmaceutical companies including Vertex Pharmaceuticals having previously failed to develop effective treatments. Current RNA editing approaches for AATD are advancing alongside other therapeutic strategies including RNA interference and base editing medicines.